Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Eos Angel Investment Syndicate
Deal Size : $4.8 million
Deal Type : Financing
Scottish Biotech ILC Therapeutics Sets Sights on Series A and IPO After Recent Investment Round
Details : The financing will be used in the development for ILC’s lead hybrid interferon drug, Alfacyte (human alpha interferon), an anti-viral medicine for the treatment of upper respiratory tract viral infections, including SARS-CoV-2 which causes Covid-19.
Product Name : Alfacyte
Product Type : Protein
Upfront Cash : Undisclosed
April 26, 2023
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Eos Angel Investment Syndicate
Deal Size : $4.8 million
Deal Type : Financing
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ILC Therapeutics Announces ‘Significant’ COVID-19 Drug Breakthrough
Details : ILC Therapeutics' unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 in cell culture than other commercially-available Interferons such as Interferon alpha 2 and Interferon beta...
Product Name : Alfacyte
Product Type : Protein
Upfront Cash : Inapplicable
July 10, 2020
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Recipient : University of St Andrews
Deal Size : Undisclosed
Deal Type : Agreement
Details : The collaborative work between ILC Therapeutics and Dr. Catherine Adamson from the School of Biology at the University of St Andrews, will focus on the role that Alfacyte can play in preventing COVID-19-indusced acute respiratory distress syndrome (ARDS)...
Product Name : Alfacyte
Product Type : Protein
Upfront Cash : Undisclosed
June 23, 2020
Lead Product(s) : Human Alpha Interferon
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Recipient : University of St Andrews
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ILC Seeks £4m to Help Advance COVID-19 Trials
Details : The company has patented a new Interferon-Alpha subtype called Interferon Alpha 14 which can be given to patients through injection or inhalation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable